Hemogenyx Pharmaceuticals plc (LSE:HEMO), a clinical-stage biopharmaceutical company, successfully secured £620,000 in funding through the issuance of convertible loan notes. This capital injection will bolster the ongoing clinical trial of HG-CT-1, a CAR-T cell therapy designed to treat relapsed or refractory acute myeloid leukemia.
The company received an investment offer from a small investor group, which proved crucial in securing this funding. The loan notes carry no interest and will automatically convert into shares.
The conversion will occur once Hemogenyx meets specific headroom requirements under the FCA’s Prospectus Rules. This is anticipated to happen on or after November 15, 2025. The conversion price is set at £5.30 per share, reflecting the closing share price on August 29, 2025.
Vladislav Sandler, CEO of Hemogenyx Pharmaceuticals, expressed his satisfaction with the progress of the HG-CT-1 Phase I clinical trial. He highlighted the investor support as a significant vote of confidence in the company’s long-term strategy. The funding, he noted, will strengthen the company’s financial position and allow for continued momentum in HG-CT-1’s development.
Hemogenyx intends to apply for the admission of the newly issued ordinary shares to trading on the London Stock Exchange. This admission is expected to be effective after November 15, 2025. The new shares will have equal status with existing shares, entitling holders to future dividends and distributions.
Hemogenyx Pharmaceuticals, headquartered in London with US subsidiaries in New York City, focuses on developing treatments for blood and autoimmune diseases. The company is developing several product candidates and platform technologies. The company’s clinical trial progress is being closely monitored by investors and industry analysts. The successful funding round is a positive indicator for the future of Hemogenyx and its ongoing research.
Related
